Literature DB >> 17216278

The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase.

E Nobecourt1, M J Davies, B E Brown, L K Curtiss, D J Bonnet, F Charlton, A S Januszewski, A J Jenkins, P J Barter, K-A Rye.   

Abstract

AIMS/HYPOTHESIS: Hyperglycaemia, one of the main features of diabetes, results in non-enzymatic glycation of plasma proteins, including apolipoprotein A-I (apoA-I), the most abundant apolipoprotein in HDL. The aim of this study was to determine how glycation affects the structure of apoA-I and its ability to activate lecithin:cholesterol acyltransferase (LCAT), a key enzyme in reverse cholesterol transport.
MATERIALS AND METHODS: Discoidal reconstituted HDL (rHDL) containing phosphatidylcholine and apoA-I ([A-I]rHDL) were prepared by the cholate dialysis method and glycated by incubation with methylglyoxal. Glycation of apoA-I was quantified as the reduction in detectable arginine, lysine and tryptophan residues. Methylglyoxal-AGE adduct formation in apoA-I was assessed by immunoblotting. (A-I)rHDL size and surface charge were determined by non-denaturing gradient gel electrophoresis and agarose gel electrophoresis, respectively. The kinetics of the LCAT reaction was investigated by incubating varying concentrations of discoidal (A-I)rHDL with a constant amount of purified enzyme. The conformation of apoA-I was assessed by surface plasmon resonance.
RESULTS: Methylglyoxal-mediated modifications of the arginine, lysine and tryptophan residues in lipid-free and lipid-associated apoA-I were time- and concentration-dependent. These modifications altered the conformation of apoA-I in regions critical for LCAT activation and lipid binding. They also decreased (A-I)rHDL size and surface charge. The rate of LCAT-mediated cholesterol esterification in (A-I)rHDL varied according to the level of apoA-I glycation and progressively decreased as the extent of apoA-I glycation increased. CONCLUSIONS/
INTERPRETATION: It is concluded that glycation of apoA-I may adversely affect reverse cholesterol transport in subjects with diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216278     DOI: 10.1007/s00125-006-0574-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

1.  Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins.

Authors:  D L Rainwater; D W Andres; A L Ford; F Lowe; P J Blanche; R M Krauss
Journal:  J Lipid Res       Date:  1992-12       Impact factor: 5.922

Review 2.  Apolipoprotein A-I: structure-function relationships.

Authors:  P G Frank; Y L Marcel
Journal:  J Lipid Res       Date:  2000-06       Impact factor: 5.922

3.  Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins.

Authors:  M Passarelli; S Catanozi; E R Nakandakare; J C Rocha; R E Morton; A F Shimabukuro; E C Quintão
Journal:  Diabetologia       Date:  1997-09       Impact factor: 10.122

4.  Advanced glycation end products and endothelial dysfunction in type 2 diabetes.

Authors:  Kathryn C B Tan; Wing-Sun Chow; Victor H G Ai; Christine Metz; Richard Bucala; Karen S L Lam
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

5.  The preferential site of non-enzymatic glycation of human apolipoprotein A-I in vivo.

Authors:  C Calvo; N Ulloa; M Campos; C Verdugo; M Ayrault-Jarrier
Journal:  Clin Chim Acta       Date:  1993-08-31       Impact factor: 3.786

6.  Preparation and characterization of spheroidal, reconstituted high-density lipoproteins with apolipoprotein A-I only or with apolipoprotein A-I and A-II.

Authors:  K A Rye; K H Garrety; P J Barter
Journal:  Biochim Biophys Acta       Date:  1993-04-23

7.  In vivo metabolism of human apoprotein A-I-phospholipid complexes. Comparison with human high density lipoprotein-apoprotein A-I metabolism.

Authors:  C L Malmendier; C Delcroix; J P Ameryckx
Journal:  Clin Chim Acta       Date:  1983-07-15       Impact factor: 3.786

8.  Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells.

Authors:  B E Brown; R T Dean; M J Davies
Journal:  Diabetologia       Date:  2005-01-20       Impact factor: 10.122

9.  Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice.

Authors:  Reigh-Yi Lin; Ernane D Reis; Anthony T Dore; Min Lu; Newsha Ghodsi; John T Fallon; Edward A Fisher; Helen Vlassara
Journal:  Atherosclerosis       Date:  2002-08       Impact factor: 5.162

10.  Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin.

Authors:  T W Lo; M E Westwood; A C McLellan; T Selwood; P J Thornalley
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

View more
  32 in total

Review 1.  Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: consequences for atherosclerosis development.

Authors:  Geesje M Dallinga-Thie; Robin P F Dullaart; Arie van Tol
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

2.  Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways.

Authors:  Sarama Saha; Juergen Graessler; Peter E H Schwarz; Claudia Goettsch; Stefan R Bornstein; Steffi Kopprasch
Journal:  Mol Cell Biochem       Date:  2012-03-01       Impact factor: 3.396

Review 3.  Lipoprotein metabolism and CKD: overview.

Authors:  Philip Barter
Journal:  Clin Exp Nephrol       Date:  2013-09-20       Impact factor: 2.801

Review 4.  Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease.

Authors:  Kerry-Anne Rye
Journal:  Clin Exp Nephrol       Date:  2013-09-20       Impact factor: 2.801

Review 5.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

6.  Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

Authors:  Estelle Nobécourt; Fatiha Tabet; Gilles Lambert; Rajesh Puranik; Shisan Bao; Ling Yan; Michael J Davies; Bronwyn E Brown; Alicia J Jenkins; Gregory J Dusting; David J Bonnet; Linda K Curtiss; Philip J Barter; Kerry-Anne Rye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-28       Impact factor: 8.311

7.  Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway.

Authors:  Baohai Shao; Subramaniam Pennathur; Ioanna Pagani; Michael N Oda; Joseph L Witztum; John F Oram; Jay W Heinecke
Journal:  J Biol Chem       Date:  2010-04-08       Impact factor: 5.157

8.  Hypolipidemic activity of Semecarpus anacardium in Streptozotocin induced diabetic rats.

Authors:  Aseervatham Jaya; Palanivelu Shanthi; Panchanatham Sachdanandam
Journal:  Endocrine       Date:  2010-06-24       Impact factor: 3.633

9.  Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus.

Authors:  Yoshifumi Kurosaki; Tomoaki Tsukushi; Shinichi Munekata; Tohru Akahoshi; Tatsumi Moriya; Zensuke Ogawa
Journal:  J Clin Lab Anal       Date:  2013-02-25       Impact factor: 2.352

10.  Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.

Authors:  E Nobécourt; J Zeng; M J Davies; B E Brown; S Yadav; P J Barter; K-A Rye
Journal:  Diabetologia       Date:  2008-04-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.